Abstract
The kidney controls erythropoietin production in adults, and the anemia that can accompany renal failure is a major medical problem. The liver controls erythropoietin production during fetal life but is silenced shortly after birth. Erythropoietin transcription is controlled by hypoxia-inducible factor (HIF), which is inhibited by three prolyl hydroxylases (PHD1, PHD2, and PHD3). Systemic PHD2 inactivation has been found to increase renal, but not hepatic, erythropoietin production. In contrast, we show here that simultaneous genetic inactivation of all three PHD paralogs in mice reactivates hepatic erythropoietin production and stimulates red blood synthesis, suggesting that pan-PHD inhibitory drugs might be useful for the treatment of anemia caused by chronic kidney disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anemia / drug therapy
-
Anemia / etiology
-
Animals
-
Erythropoiesis
-
Erythropoietin / biosynthesis*
-
Erythropoietin / genetics
-
Hematocrit
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Hypoxia-Inducible Factor-Proline Dioxygenases
-
Kidney Failure, Chronic / complications
-
Liver / enzymology
-
Liver / metabolism*
-
Mice
-
Procollagen-Proline Dioxygenase / antagonists & inhibitors
-
Procollagen-Proline Dioxygenase / genetics
-
Procollagen-Proline Dioxygenase / metabolism
-
Transcription Factors / genetics
-
Transcription Factors / metabolism
Substances
-
HIF-2 protein, mouse
-
Hif1a protein, mouse
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Transcription Factors
-
Erythropoietin
-
PHD1 protein, mouse
-
PHD3 protein, mouse
-
Procollagen-Proline Dioxygenase
-
Egln1 protein, mouse
-
Hypoxia-Inducible Factor-Proline Dioxygenases